Literature DB >> 36147608

Current trends in diagnosis and management of follicular lymphoma.

Gopila Gupta1, Vikas Garg2, Saumyaranjan Mallick3, Ajay Gogia2.   

Abstract

Follicular lymphoma (FL) originates from germinal center B cells, is the most prevalent form of indolent non-Hodgkin's lymphoma. Upfront management is based on stage, grade, and disease burden. Radiotherapy may be curative in limited disease while chemoimmunotherapy is preferred in advanced disease. Maintenance therapy is routinely administered but its role is debatable. Relapses are common and interval from initial therapy to relapse is most important prognostic factor for relapsed FL. Management of relapsed patients is based on the initial management, the interval from prior therapies, and the toxicity of available therapies. Multiple agents are available for patients after two or more lines of therapy, but sequencing remains poorly defined. AJBR
Copyright © 2022.

Entities:  

Keywords:  CART; EZH2; FL; Follicular lymphoma; NHL; PI3K; chemoimmunotherapy; non-Hodgkin’s lymphoma

Year:  2022        PMID: 36147608      PMCID: PMC9490109     

Source DB:  PubMed          Journal:  Am J Blood Res        ISSN: 2160-1992


  107 in total

1.  Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

Authors:  Roswitha Forstpointner; Michael Unterhalt; Martin Dreyling; Hans-Peter Böck; Roland Repp; Hannes Wandt; Christiane Pott; John F Seymour; Bernd Metzner; Annette Hänel; Tanja Lehmann; Frank Hartmann; Hermann Einsele; Wolfgang Hiddemann
Journal:  Blood       Date:  2006-08-31       Impact factor: 22.113

2.  The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL).

Authors:  S Luminari; I Biasoli; A Versari; S Rattotti; C Bottelli; C Rusconi; F Merli; M Spina; A J M Ferreri; P L Zinzani; A Gallamini; A Franceschetto; C Boccomini; S Franceschetti; F Salvi; F D Raimondo; A M Carella; Q Micol; M Balzarotti; P Musto; M Federico
Journal:  Ann Oncol       Date:  2014-01-10       Impact factor: 32.976

Review 3.  Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines.

Authors:  Andrew Wirth; N George Mikhaeel; Berthe M P Aleman; Chelsea C Pinnix; Louis S Constine; Umberto Ricardi; Tim M Illidge; Hans Theodor Eich; Bradford S Hoppe; Bouthaina Dabaja; Andrea K Ng; Youlia Kirova; Anne Kiil Berthelsen; Karin Dieckmann; Joachim Yahalom; Lena Specht
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-04-07       Impact factor: 7.038

4.  Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.

Authors:  John F Seymour; Robert Marcus; Andrew Davies; Eve Gallop-Evans; Andrew Grigg; Andrew Haynes; Michael Herold; Thomas Illmer; Herman Nilsson-Ehle; Martin Sökler; Ulrich Dünzinger; Tina Nielsen; Aino Launonen; Wolfgang Hiddemann
Journal:  Haematologica       Date:  2020-05       Impact factor: 9.941

5.  Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Brice; Y Bastion; E Lepage; N Brousse; C Haïoun; P Moreau; N Straetmans; H Tilly; I Tabah; P Solal-Céligny
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

6.  Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03.

Authors:  Michael MacManus; Richard Fisher; Daniel Roos; Peter O'Brien; Andrew Macann; Sidney Davis; Richard Tsang; David Christie; Bev McClure; David Joseph; Jayasingham Jayamohan; John F Seymour
Journal:  J Clin Oncol       Date:  2018-07-05       Impact factor: 44.544

7.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.

Authors:  Wendy Béguelin; Relja Popovic; Matt Teater; Yanwen Jiang; Karen L Bunting; Monica Rosen; Hao Shen; Shao Ning Yang; Ling Wang; Teresa Ezponda; Eva Martinez-Garcia; Haikuo Zhang; Yupeng Zheng; Sharad K Verma; Michael T McCabe; Heidi M Ott; Glenn S Van Aller; Ryan G Kruger; Yan Liu; Charles F McHugh; David W Scott; Young Rock Chung; Neil Kelleher; Rita Shaknovich; Caretha L Creasy; Randy D Gascoyne; Kwok-Kin Wong; Leandro Cerchietti; Ross L Levine; Omar Abdel-Wahab; Jonathan D Licht; Olivier Elemento; Ari M Melnick
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

8.  Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.

Authors:  Brian K Link; Matthew J Maurer; Grzegorz S Nowakowski; Stephen M Ansell; William R Macon; Sergei I Syrbu; Susan L Slager; Carrie A Thompson; David J Inwards; Patrick B Johnston; Joseph P Colgan; Thomas E Witzig; Thomas M Habermann; James R Cerhan
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

9.  Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.

Authors:  Clémentine Sarkozy; Marek Trneny; Luc Xerri; Nick Wickham; Pierre Feugier; Sirpa Leppa; Pauline Brice; Pierre Soubeyran; Maria Gomes Da Silva; Christiane Mounier; Fritz Offner; Jehan Dupuis; Dolores Caballero; Danielle Canioni; Marlton Paula; Richard Delarue; Pierre Zachee; John Seymour; Gilles Salles; Hervé Tilly
Journal:  J Clin Oncol       Date:  2016-06-13       Impact factor: 44.544

10.  Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

Authors:  Lindsay M Morton; Susan L Slager; James R Cerhan; Sophia S Wang; Claire M Vajdic; Christine F Skibola; Paige M Bracci; Silvia de Sanjosé; Karin E Smedby; Brian C H Chiu; Yawei Zhang; Sam M Mbulaiteye; Alain Monnereau; Jennifer J Turner; Jacqueline Clavel; Hans-Olov Adami; Ellen T Chang; Bengt Glimelius; Henrik Hjalgrim; Mads Melbye; Paolo Crosignani; Simonetta di Lollo; Lucia Miligi; Oriana Nanni; Valerio Ramazzotti; Stefania Rodella; Adele Seniori Costantini; Emanuele Stagnaro; Rosario Tumino; Carla Vindigni; Paolo Vineis; Nikolaus Becker; Yolanda Benavente; Paolo Boffetta; Paul Brennan; Pierluigi Cocco; Lenka Foretova; Marc Maynadié; Alexandra Nieters; Anthony Staines; Joanne S Colt; Wendy Cozen; Scott Davis; Anneclaire J de Roos; Patricia Hartge; Nathaniel Rothman; Richard K Severson; Elizabeth A Holly; Timothy G Call; Andrew L Feldman; Thomas M Habermann; Mark Liebow; Aaron Blair; Kenneth P Cantor; Eleanor V Kane; Tracy Lightfoot; Eve Roman; Alex Smith; Angela Brooks-Wilson; Joseph M Connors; Randy D Gascoyne; John J Spinelli; Bruce K Armstrong; Anne Kricker; Theodore R Holford; Qing Lan; Tongzhang Zheng; Laurent Orsi; Luigino Dal Maso; Silvia Franceschi; Carlo La Vecchia; Eva Negri; Diego Serraino; Leslie Bernstein; Alexandra Levine; Jonathan W Friedberg; Jennifer L Kelly; Sonja I Berndt; Brenda M Birmann; Christina A Clarke; Christopher R Flowers; James M Foran; Marshall E Kadin; Ora Paltiel; Dennis D Weisenburger; Martha S Linet; Joshua N Sampson
Journal:  J Natl Cancer Inst Monogr       Date:  2014-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.